Emerging technologies for enabling proangiogenic therapy

Nanotechnology

Volumn 22, Issue 49, 2011, Pages

  Roy, Rituparna Sinha ^a   Roy, Bhaskar ^b,c,d   Sengupta, Shiladitya ^c,d,e  

^a BIDHAN CHANDRA KRISHI VISWAVIDYALAYA   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY   (India)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICALLY ACTIVE PROTEINS; CLINICAL PROBLEMS; EMERGING TECHNOLOGIES; GROWTH FACTOR; PRO-ANGIOGENIC THERAPIES; PROTEIN ENGINEERING; THERAPEUTIC ANGIOGENESIS;

BIOLOGICAL MATERIALS; DISEASE CONTROL; GENETIC ENGINEERING; PATHOLOGY;

PROTEINS;

ANGIOGENIC FACTOR; NANOPARTICLE; SIGNAL PEPTIDE;

ANGIOGENESIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; METHODOLOGY; PROTEIN ENGINEERING; REVIEW; TISSUE ENGINEERING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; NANOPARTICLES; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN ENGINEERING; TISSUE ENGINEERING;

EID: 81855220953     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/22/49/494004     Document Type: Article

References (86)

1. Ferrara N and Kerbel R S 2005 Angiogenesis as a therapeutic target Nature 438 967-74 (Pubitemid 43093963)
2. Carmeliet P 2005 Angiogenesis in life, disease and medicine Nature 438 932-6 (Pubitemid 43093958)
3. Risau W 1997 Mechanism of angiogenesis Nature 386 671-4
4. Gurtner G C, Callaghan M J and Longaker M T 2007 Progress and potential for regenerative medicine Annu. Rev. Med. 58 299-312 (Pubitemid 46706516)
5. Kutryk M J B, Kassam S A and Stewart D J 2001 Angiogenesis: an emerging technology for the treatment of coronary artery disease Cardiol. Rounds VI 1-8
6. Fischer C, Schneider M and Carmeliet P 2006 Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis Handbook of Experimental Pharmacology vol 176/II (Heidelberg: Springer) pp157-212
7. McKinnon H, Gherardi E, Reidy M and Bowyer D 2006 Hepatocyte growth factor/scatter factor and MET are involved in arterial repair and atherogenesis Am. J. Pathol. 168 340-8 (Pubitemid 43062585)
8. Jin H, Yang R, Li W, Ogasawara A K, Schwall R, Eberhard D A, Zheng Z, Kahn D and Paoni N F 2003 Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction Pharm. Exp. Ther. 304 654-66
9. Annex B H and Simons M 2005 Growth factor-induced therapeutic angiogenesis in the heart: protein therapy Cardiovasc. Res. 65 649-55 (Pubitemid 40138985)
10. Phelps E A and Garcia A J 2009 Update on therapeutic vascularization strategies Regen. Med. 4 65-80
11. Moon J J and West J L 2008 Vascularization of engineered tissues: approaches to promote angiogenesis in biomaterials Curr. Top. Med. Chem. 8 300-10 (Pubitemid 351791025)
12. Cao Y 2010 Therapeutic angiogenesis for ischemic disorders: what is missing for clinical benefits? Discov. Med. 9 179-84
13. Zachary I and Morgan R D 2011 Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects Heart 97 181-9
14. Cao Y, Hong A, Schulten H and Post M J 2005 Update on therapeutic neovascularization Cardiovasc. Res. 65 639-48 (Pubitemid 40138984)
15. Jacobs J 2007 Combating cardiovascular disease with angiogenic therapy Drug Discov. Today 12 1040-5 (Pubitemid 350180559)
16. www.americanheart.org
17. Sneider E B, Nowicki P T and Messina L M 2009 Regenerative medicine in the treatment of peripheral arterial disease J. Cell. Biochem. 108 753-61
18. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post M J, Wahlberg E, Leboulch P and Cao Y 2003 Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 Nature Med. 9 604-13 (Pubitemid 36597108)
19. Cao Y 2009 Monotherapy versus combination therapy of angiogenic and arteriogenic factors for the treatment of ischemic disorders Curr. Mol. Med. 9 967-72
20. Simons M et al 2000 Clinical trials in coronery angiogenesis: issues, problems, consensus: an expert panel summary Circulation 102 e73-86
21. Gilbert S F (ed) Developmental Biology 6th edn (Sunderland, MA: Sinauer Associates) chapter 15 (Lateral Plate Mesoderm) Part 3
22. Jones D S, Silverman A P and Cochran J R 2008 Developing therapeutic proteins by engineering ligand receptor interactions Trends Biotechnol. 26 498-505
23. Sinha Roy R et al 2010 Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis Proc. Natl Acad. Sci. USA 107 13608-13
24. Zakrzewska M, Krowarsch D, Wiedlocha A and Otlewski J 2004 Design of fully active FGF-1 variants with increased stability Protein Eng., Des. Sel. 17 603-11 (Pubitemid 39665397)
25. Zakrzewska M, Krowarsch D, Wiedlocha A, Olsnes S and Otlewski J 2005 Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action J. Mol. Biol. 352 860-75 (Pubitemid 41267073)
26. Szlachcic A, Zakrzewska M, Krowarsch D, Os V, Helland R, Smalas A O and Otlewski J 2009 Structure of a highly stable mutant of human fibroblast growth factor 1 Acta Crystallogr. D Biol. Crystallogr. D65 67-73
27. Gherardi E et al 2006 Structural basis of hepatocyte growth factor/scatter factor and MET signaling Proc. Natl Acad. Sci. USA 103 4046-51
28. Sengupta S, Gherardi E, Sellers L A, Wood J M and Sasisekharan R 2003 Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor Arterioscler., Thromb., Vasc. Biol. 23 69-75 (Pubitemid 36091628)
29. Sengupta S, Sellers L A, Li R C, Gherardi E, Zhao G, Watson N, Sasisekharan R and Fan T P 2003 Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis Circulation 107 2955-61 (Pubitemid 36736639)
30. Sengupta S, Sellers L A, Cindrova T, Skepper J, Gherardi E, Sasisekharan R and Fan T P 2003 Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis Cancer Res. 63 8351-9 (Pubitemid 37549489)
31. Holmes O, Pillozzi S, Deakin J A, Carafoli F, Kemp L, Butler P J, Lyon M and Gherardi E 2007 Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domain J. Mol. Biol. 367 395-408 (Pubitemid 46295423)
32. Schwall R H, Chang L Y, Godowski P J, Kahn D W, Hillan K J, Bauer K D and Zioncheck T F 1996 Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2 JCB 113 709-18 (Pubitemid 26163342)
33. Lietha D, Chirgadze D Y, Mulloy B, Blundell T L and Gherardi E 2001 Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor EMBO J. 20 5543-55 (Pubitemid 33010032)
34. Richardson T P, Peters M C, Ennett A B and Mooney D J 2001 Polymeric system for dual growth factor delivery Nature Biotechnol. 19 1029-34 (Pubitemid 33041886)
35. Chen R R, Silva E A, Yuen W W and Mooney D J 2007 Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation Pharm. Res. 24 258-64 (Pubitemid 46072185)
36. Chen R R, Silva E A, Yuen W W, Brock A A, Fischbach C, Lin A S, Guldberg R E and Mooney D J 2007 Integrated approach to designing growth factor delivery systems FASEB J. 21 3896-903 (Pubitemid 350232347)
37. Chapanian R and Amsden B G 2010 Combined and sequential delivery of bioactive VEGF165 and HGF from poly(trimethylene carbonate) based photo-cross-linked elastomers J. Control. Release 143 53-63
38. Lee K, Silva E A and Mooney D J 2011 Growth factor delivery-based tissue engineering: general approaches and a review of recent developments J. R. Soc. Interface 8 153-70
39. Anitua E, Sanchez M, Orive G and Andia I 2008 Delivering growth factors for therapeutics Trends Pharmacol. Sci. 29 37-41
40. Post M J, Laham R, Sellke F W and Simons M 2001 Therapeutic angiogenesis in cardiology using protein formulations Cardiovasc. Res. 49 522-31 (Pubitemid 32146415)
41. Sun Q, Silva E A, Wang A, Fritton J C, Mooney D J, Schaffler M B, Grossman P M and Rajagopalan S 2010 Sustained release of multiple growth factors from injectable polymeric system as a novel therapeutic approach towards angiogenesis Pharm. Res. 27 264-71
42. Greenberg J I et al 2008 A role for VEGF as a negative regulator of pericyte function and vessel maturation Nature 456 809-13
43. Cleland J L, Duenas E T, Park A, Daugherty A, Kahn J, Kowalski J and Cuthbertson A 2001 Development of poly-(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis J. Control. Release 72 13-24 (Pubitemid 32522340)
44. Bhise N S, Shmueli R B, Sunshine J C, Tzeng S Y and Green J J 2011 Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis Expert Opin. 8 485-504
45. Epstein S E, Fuchs S, Zhou Y F, Baffour R and Kornowski R 2001 Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc. Res. 49 532-42 (Pubitemid 32146416)
46. Uhrich K E, Cannizzaro S M, Langer R S and Shakesheff K M 1999 Polymeric systems for controlled drug release Chem. Rev. 99 3181-98 (Pubitemid 129583051)
47. Ulijn R V, Bibi N, Jayawarna V, Thornton P D, Todd S J, Mart R J, Smith A M and Gough J E 2007 Bioresponsive hydrogels Mater. Today 10 40-8 (Pubitemid 46603076)
48. Slaughter B V, Khurshid S S, Fisher O Z, Khademhosseini A and Peppas W N A 2009 Hydrogels in regenerative medicine Adv. Mater. 21 3307-29
49. Geckil H, Xu F, Zhang X, Moon S and Demirci U 2010 Engineering hydrogels as extracellular matrix mimics Nanomedicine 5 469-84
50. Amsden B G 2010 Liquid, injectable, hydrophobic and biodegradable polymers as drug delivery vehicles Macromol. Biosci. 10 825-35
51. Chung H J and Park T G 2007 Surface engineered and drug releasing pre-fabricated scaffolds for tissue engineering Adv. Drug Deliv. Rev. 59 249-62 (Pubitemid 46879969)
52. Jahanshahi M and Babaei Z 2008 Protein nanoparticle: a unique system as drug delivery vehicles Afr. J. Biotechnol. 7 4926-34
53. Shetty R C 2006 Benefits of nanotechnology in cardiovascular surgery-review of potential applications US Cardiovasc. Dis. 3
54. Mulder W J M and Fayad Z A 2008 Nanomedicine captures cardiovascular disease Arterioscler., Thromb., Vasc. Biol. 28 801-2 (Pubitemid 351544088)
55. Kubo M et al 2009 therapeutic neovascularization by nanotechnology- mediated cell-selective delivery of pitavastatin into the vascular endothelium Arterioscler., Thromb., Vasc. Biol. 29 796-801
56. Rocha F G, Sundback C A, Krebs N J, Leach J K, Mooney D J, Ashley S W, Vacanti J P and Whang E E 2008 The effect of sustained delivery of vascular endothelial growth factor on angiogenesis in tissue-engineered intestine Biomaterials 29 2884-90
57. Chappell J C, Song J, Burke C W, Klibanov A L and Price R J 2008 Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis Small 4 1769-77
58. Golub J S, Kim Y T, Duvall C L, Bellamkonda R V, Gupta D, Lin A S, Weiss D, Robert Taylor W and Guldberg R E 2010 Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth Am. J. Physiol.-Heart C 298 H1959-65
59. d'Angelo I, Garcia-Fuentes M, Parajo Y, Welle A, Vantus T, Horvath A, Bokonyi G, Keri G and Alonso M J 2010 Nanoparticles based on PLGA:poloxamer blends for the delivery of proangiogenic growth factors Mol. Pharmaceut. 7 1724-33
60. Chung Y I, Kim S K, Lee Y K, Park S J, Cho K O, Yuk S H, Tae G and Kim Y H 2010 Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex J. Control. Release 143 282-9
61. Huang M, Vitharana S N, Peek L J, Coop T and Berkland C 2007 Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor Biomacromolecules 8 1607-14 (Pubitemid 46865135)
62. Parajo Y, d'Angelo I, Welle A, Garcia-Fuentes M and Alonso A J 2010 Hyaluronic acid/chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB Drug Deliv. 17 596-604
63. Fu K, Pack D W, Klibanov A M and Langer R 2000 Visual evidence of acidic environment within degrading poly(lactic-co-glycolide) (PLGA) microspheres Pharm. Res. 17 100-6 (Pubitemid 30121107)
64. Shenderova A, Burke T G and Schwendeman S P 1997 Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles Pharm. Res. 14 1406-14 (Pubitemid 27481072)
65. Ekholm M, Hietanen J, Lindqvist C, Rautavuori J, Santavirta S and Suuronen R 1999 Histological study of tissue reactions to ε-caprolactone- lactide copolymer in paste form Biomaterials 20 1257-62 (Pubitemid 29281376)
66. Zhu G Z, Mallery S R and Schwendeman S P 2000 Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide) Nature Biotechnol. 18 52-7 (Pubitemid 30041172)
67. Ding A G and Schwendeman S P 2008 Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy Pharm. Res. 25 2041-52
68. Jiang W and Schwendeman S P 2001 Stabilization and controlled release of bovine serum albumin encapsulated in poly(D,L-lactide) and poly(ethylene glycol) microsphere beads Pharm. Res. 18 878-85 (Pubitemid 32783527)
69. Zhu X H, Wang C H and Tong Y W 2009 Invitro characterization of hepatocyte growth factor release from PHBV/PLGA microsphere scaffold J. Biomed. Mater. Res. A 89 411-23
70. Domb A J, Kost J and Wiseman D 1998 Handbook of Biodegradable Polymers (Amsterdam: Harwood Academic)
71. Sohier J, Vlugt T J, Cabrol N, Van Blitterswijk C, de Groot K and Bezemer J M 2006 Dual release of proteins from porous polymeric scaffolds J. Control. Release 111 95-106 (Pubitemid 43292485)
72. Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G and Cohen S 2003 Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres J. Biomed. Mater. Res. A 65 489-97 (Pubitemid 38075880)
73. Wei G B, Jin Q, Giannobile W V and Ma P X 2006 Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB J. Control. Release 112 103-10
74. Murphy W L, Peters M C, Kohn D H and Mooney D J 2000 Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering Biomaterials 21 2521-7
75. Hile D D and Pishko M V 2004 Solvent-free protein encapsulation within biodegradable polymer foams Drug Deliv. 11 287-93 (Pubitemid 39331999)
76. Guan J, Stankus J J and Wagner W R 2007 Biodegradable elastomeric scaffolds with basic fibroblast growth factor release J. Control. Release 120 70-8 (Pubitemid 46874620)
77. Ziegler J, Mayr-Wohlfart U, Kessler S, Breitig D and Gunther K P 2002 Adsorption and release properties of growth factors from biodegradable implants J Biomed. Mater. Res. 59 422-8 (Pubitemid 34037485)
78. Yoon J J, Chung H J, Lee H J and Park T G 2006 Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor J. Biomed. Mater. Res. A 79 934-42 (Pubitemid 44915914)
79. Burke P A 2000 Controlled release protein therapeutics: effects of process and formulation on stability Handbook of Pharmaceutical Controlled Release Technology ed D L Wise (New York: Dekker) chapter 32, pp 661-92
80. Burdick J A and Prestwich G D 2011 Hyaluronic acid hydrogels for biomedical applications Adv. Mater. 23 H41-56
81. Hao X, Silva E A, Mansson-Broberg A, Grinnemo K H, Siddiqui A J, Dellgren G, Wardell E, Brodin L A, Mooney D J and Sylven C 2007 Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction Cardiovasc. Res. 75 178-85 (Pubitemid 46876668)
82. Ishihara M et al 2006 Chitosan hydrogel as a drug delivery carrier to control angiogenesis J. Artif. Organs 9 8-16
83. Layman H, Sacasa M, Murphy A E, Murphy A M, Pham S M and Andreopoulos F M 2009 Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model Acta Biomater. 5 230-9
84. van de Weert M, van Steenbergen M J, Cleland J L, Heller J, Hennink W E and Crommelin D J A 2002 Semisolid, self-catalysed poly(ortho ester)s as controlled release systems: protein release and protein stability issues J. Pharm. Sci. 91 1065-74
85. Amsden B G, Timbart L, Marecak D, Chapanian R, Tse M Y and Pang S C 2010 VEGF-induced angiogenesis following localized delivery via injectable, low viscosity poly(trimethylene carbonate) J. Control. Release 145 109-15
86. Ehrbar M, Schoenmakers R, Christen E H, Fussenegger M and Weber W 2008 Drug-sensing hydrogels for the inducible release of biopharmaceuticals Nature Matter 7 800-4